Review of the pericyte during angiogenesis and its role in cancer and diabetic retinopathy.
Hall
Anthony P
AP
AstraZeneca R&D Alderley Park, Safety Assessment UK, Mereside, Alderley Park, Macclesfield, SK10 4TG Cheshire, England. Peter.A.Hall@astrazeneca.com
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D042501:Angiogenic Proteins / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D002454:Cell Differentiation; D019070:Cell Lineage; D003930:Diabetic Retinopathy / Q000473:pathology*; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000473:pathology*; D009389:Neovascularization, Pathologic; D018919:Neovascularization, Physiologic; D020286:Pericytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D015861:Retinal Neovascularization / Q000473:pathology; D012171:Retinal Vessels / Q000473:pathology*
D020533:Angiogenesis Inhibitors; D042501:Angiogenic Proteins; D000970:Antineoplastic Agents